Nuwellis reported Q4 revenue of USD 2.4 million, up 9% sequentially, driven by higher U.S. console sales, an 11% increase in circuit average selling price, and a non-recurring increase in international sales tied to customer last-time buys. Q4 gross margin was 68.2%, up 10 percentage points year over year, reflecting improved pricing and product mix. Q4 operating loss was USD 2.4 million and net loss attributable to common shareholders was USD 2.4 million. For FY 2025, revenue was USD 8.3 million, down 5%, with Heart Failure revenue up 8% and Pediatrics up 14% while Critical Care declined 19%. Nuwellis ended 2025 with no debt and about USD 1.2 million in cash, cash equivalents and restricted cash, and said it closed a USD 5 million private placement and warrant inducement transaction in January 2026 and signed a definitive agreement to acquire Rendiatech.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100815PRIMZONEFULLFEED9668851) on March 10, 2026, and is solely responsible for the information contained therein.